The phrase "advanced validation" is correct and usable in written English.
It can be used in contexts where you are discussing processes or methods that involve thorough checks or assessments, often in technical or professional settings.
Example: "The software includes advanced validation features to ensure data integrity and accuracy before submission."
Alternatives: "enhanced verification" or "sophisticated checking".
A summary of the original manufacturer-recommended assay parameters, and the various modifications we made to support advanced validation can be found in Table II.
During pre-validation method development, we systematically examined every aspect of the method, and made significant modifications when required to fulfill advanced validation requirements.
In conclusion, we have conducted the first GLP-level method development and advanced validation of a method for the quantitation of Aβ42 in human CSF.
In this present study, we have demonstrated that the INNOTEST Aβ42 assay meets advanced validation criteria when an MRD is incorporated, and is thus useful for measuring drug induced biomarker changes.
Advanced validation ("reproducibility testing") ensures that the mathematical representation of the model can be evaluated and that the model is reproducible using the raw data in the archive.
The use of surrogate tissue resources including tumor cell lines for the early discovery phases in melanoma, as used in this study, will undoubtedly allow for the conservation of precious tissue specimens for use in more advanced validation studies.
Internal and advanced internal validation demonstrated the strong prediction ability of the model.
Firstly, we will advance the validation of a number of relevant constructs relevant to advancing quality improvement systems in European hospitals.
The promising results recommend the integration of cellular studies in the field of inhalation toxicology and their regulatory acceptance by advancing appropriate validation studies.
Comprehensively, this study makes a number of contributive advances: (i) we present further validation of PHYRN-based inference in an ancient protein family with variable rates, and (ii) we derive a refined model of recA/RAD51 evolution.
Currently, flow cytometric (tetraploidy, aneuploidy)[46] and loss of heterozygosity (LOH) at the p53 locus[47] have advanced regarding biomarker validation in large-scale phase 4 studies as defined by EDRN classification.
